p53 and apoptosis alterations in keloids and keloid fibroblasts

Wound Repair and Regeneration

Volumn 6, Issue 1, 1998, Pages 28-37

  Ladin, Daniel A ^a   Hou, Zizheng ^a   Patel, Dipa ^a   Mcphail, Monica ^a   Olson, Jennifer C ^a   Saed, Ghassan M ^a   Fivenson, David P ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FAS ANTIGEN; GAMMA INTERFERON; HYDROCORTISONE; PROTEIN BCL 2; PROTEIN P53;

ADULT; APOPTOSIS; ARTICLE; CELL CULTURE; DRUG EFFECT; ENZYME IMMUNOASSAY; FIBROBLAST; HUMAN; KELOID; NEEDLE BIOPSY; PATHOLOGY; RANDOMIZATION; REFERENCE VALUE; SKIN; WESTERN BLOTTING;

ADULT; ANTIGENS, CD95; APOPTOSIS; BIOPSY, NEEDLE; BLOTTING, WESTERN; CELLS, CULTURED; DNA; FIBROBLASTS; HUMANS; HYDROCORTISONE; IMMUNOENZYME TECHNIQUES; INTERFERON TYPE II; KELOID; PROTO-ONCOGENE PROTEINS C-BCL-2; RANDOM ALLOCATION; REFERENCE VALUES; SKIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031598567     PISSN: 10671927     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-475X.1998.60106.x     Document Type: Article

References (27)

1. Alhady S. Keloids. Plast Reconstr Surg 1969;44:564-6.
2. Ladin DA, Garner WL, Smith DJ. Excessive scarring as a consequence of healing. Wound Rep Reg 1995;3:6-14.
3. Nemeth AJ. Keloids and hypertrophic scars. J Dermatol Surg Oncol 1993;19:738-46.
4. Russell SB, Trupin KM, Rodriguez-Eaton S, Russell JD, Trupin JS. Reduced growth-factor requirement of keloid derived fibroblasts may account for tumor growth. Proc Natl Acad Sci USA 1988;85:587-91.
5. Haisa M, Okochi H, Grotendorst G. Elevated levels of PDGF alpha receptors in keloid fibroblasts contribute to an enhanced response to PDGF. J Invest Dermatol 1994;103:560-3.
6. Harris AL. Mutant p53: the commonest genetic abnormality in human cancer? J Pathol 1990;162:5-6.
7. Lane DP, Benchimol S. p53: oncogene or anti-oncogene? Gen Dev 1990;4:1-8.
8. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53 negative response element in the bcl-2 gene. Cancer Res 1994;54:3131-5.
9. Thompson CB. Apoptosis and the pathogenesis and treatment of disease. Science 1995;267:1456-62.
10. Kischer CW, Thies AC, Chvapil M. Perivascular myofibroblasts and microvascular occlusion in hypertrophic scars and keloids. Hum Pathol 1982;13:819-24.
11. Chopp M, Zhang Z, Freytag S. p53 Expression in brain after middle cerebral artery occlusion in the rat. Biochem Biophys Res Commun 1992;182:1201-7.
12. Shimizu S, Eguchi Y, Kosaka H, Kamiike W, Matsuda H, Tsujimoto YL. Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL. Nature 1995;374:811-3.
13. Omo-Dare P. Genetic studies on keloid. J Natl Med Assoc 1975;67:428-32.
14. Bloom D. Heredity of keloids: review of the literature and report of a family with multiple keloids in five generations. NY State J Med 1956;56:511-9.
15. Laurentaci G. Dioguardi D. HLA antigens in keloids and hypertrophic scars. Arch Dermatol 1977;113:1726.
16. van der Berg FM, Baas IO, Polak MM, Offerhaus GJA. Detection of p53 overexpression in routinely paraffin embedded tissue of human carcinomas using a novel target unmasking fluid (TUF). Am J Pathol 1993;142: 381-5.
17. Fivenson DP, Douglass MC, Nickoloff BJ. Cutaneous expression of Thy-1 in mycosis fungoides. Am J Pathol 1992;141:1373-80.
18. Hou Z, Saed G, Fivenson D, Ladin D. Hypoxia does not alter cytokine production by keloid fibroblasts. J Invest Dermatol 1995;104:669 (abstract).
19. Take Y, Kumano M, Teraola H, Nishimura S, Okuyama A. DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-type p53 induced by adriamycin. Biochem Biophys Res Commun 1996;221:207-12.
20. Canman CE, Gilmer TM, Coutts SB, Kastan MB. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 1995;9:600-11.
21. Nunez G, Merino R, Grillot D, Gonzalez-Garcia M. Bcl-2 and Bcl-x: regulatory switches for lymphoid death and survival. Immunol Today 1994;15:582-8.
22. Appleton I, Brown NJ, Willoughby DA. Apoptoisis, necrosis and proliferation: possible implications in the etiology of keloids. Am J Pathol 1996;149:1441-7.
23. Granstein RD, Rook A, Flotte TJ, Haas A, Gallo RL, Jaffe HS, Amento EP. A controlled trial of intralesional recombinant interferon-gamma in the treatment of keloidal scarring: clinical and histologic findings. Arch Dermatol 1990;126: 1295-1302.
24. Kato Y, Morikawa A, Sugiyama T, Koide N, Jiang GZ, Lwin T, Yoshida T, Yokochi T. Augmentation of lipopolysaccharide-induced thymocyte apoptosis by interferon-gamma. Cell Immunol 1997;177:103-8.
25. Gold M. Topical silicone gel sheeting in the treatment of hypertrophic scars and keloids. A dermatologic experience. J Dermatol Surg Oncol 1993;19:912-6.
26. Falanga V, Martin TA, Takagi H, Kirsner RS, Helfman T, Pardes J, Ochoa MS. Low oxygen tension increases mRNA levels of alpha 1 (I) procollagen in human dermal fibroblasts. J Cell Physiol 1993;157: 408-12.
27. Hayrati E, Hoomand A. The keloidal diathesis: a resistant state to malignancies. Plast Reconstr Surg 1977;59:555-9.